Daniel Zimmerman, MD
Infectious Disease · Lincolnshire, ILNPI 1558357566
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $100 of the $159 with a category attached, or 62.8%. Comsort, Inc accounts for 62.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $113 and has fallen 70.5% since, to $33 in 2025. That places this record below the midpoint for infectious disease clinicians in IL, where the typical reported total is $182.
Across 4 payments — averaging $39.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Comsort, Inc$100
- Vertex$33
- Shionogi Inc$13
- Merck$13
Across 6 payments — averaging $23,556 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$141K
What the payments were for
- Consulting fees$10063%
- Food & beverage$3321%
- Education$2616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Comsort, Inc | 1 | $100 |
| Vertex | 1 | $33 |
| Shionogi Inc | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIVEXTRO$100
How this compares
$159 in reported general payments places this provider in the 45th percentile of 368 infectious disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZerbaxaCeftolozane/Tazobactam | 71 | $232,348 |
| Vancomycin Hcl | 103 | $8,977 |
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 121 | $8,074 |
| CeftriaxoneCeftriaxone Sodium | 45 | $3,205 |
| Cefpodoxime Proxetil | 16 | $2,488 |
| Azithromycin | 205 | $1,006 |
| Amoxicillin | 38 | $639 |
| Sodium Chloride0.9 % Sodium Chloride | 66 | $555 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $513 |
| Doxycycline Hyclate | 23 | $499 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 28 | $468 |
| Cephalexin | 19 | $390 |
| Ciprofloxacin Hcl | 19 | $279 |
| Acetazolamide | 13 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckZerbaxa | $13 | $232,34871 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 368 infectious disease providers in Illinois.
Other infectious disease in Lincolnshire
- Frank PalellaChicago$987K
- Jeffrey ShermanDeerfield$527K
- Catherine CreticosChicago$335K
- Babafemi TaiwoChicago$292K
- Beverly ShaChicago$202K
- Chad ZawitzChicago$193K
- Nancy GlickChicago$186K
- Kamaljit SinghChicago$138K
- Jorge ParadaMaywood$128K
- James SullivanChicago$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.